Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer

Molecular and Cellular Biochemistry

Volumn 404, Issue 1-2, 2015, Pages 251-257

  Huang, Ruixue ^a   Huang, Dequn ^b   Dai, Weirong ^c   Yang, Fei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ZHUZHOU CENTRAL HOSPITAL   (China)

^c Hunan Prevention and Treatment Institute of Occupational Diseases   (China)

Author keywords

Biomarker; Breast cancer; HMGA1; Prognosis

Indexed keywords

HIGH MOBILITY GROUP A1 PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; HIGH MOBILITY GROUP A1A PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA1A PROTEIN; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS;

EID: 84941739526     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2384-4     Document Type: Article

References (27)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
2. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6(5):391–401
3. Cowin P, Rowlands TM, Hatsell SJ (2005) Cadherins and castenins in breast cancer. Curr Opin Cell Biol 17(5):499–508. doi:10.1016/j.ceb.2005.08.014
4. Shah SN, Resar LM (2012) High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 27(5):567–579
5. Cleynen I, Van de Ven WJ (2008) The HMGA proteins: a myriad of functions (Review). Int J Oncol 32(2):289–305
6. Pogna EA, Clayton AL, Mahadevan LC (2010) Signalling to chromatin through post-translational modifications of HMGN. Biochim Biophys Acta 1799(1–2):93–100. doi:10.1016/j.bbagrm.2009.11.018
7. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA (1993) Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 53(22):5512–5516
8. Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA (1996) A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 74(4):573–578
9. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V, Fusco A (1996) Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 56(8):1896–1901
10. Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, D’Aiuto G, Fedele M, Iuliano R, Palmieri EA, Pierantoni GM, Giancotti V, Fusco A (2004) HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res 10(22):7637–7644. doi:10.1158/1078-0432.ccr-04-0291
11. Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, Fujioka Y, Chiappetta G, Fusco A, Atomi Y (2000) Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 60(12):3117–3122
12. Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G, Giancotti V, Viglietto G, Scambia G, Fusco A (2003) HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24(7):1191–1198. doi:10.1093/carcin/bgg075
13. Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, Kohwi-Shigematsu T (1999) HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 59(22):5695–5703
14. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G (2013) HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 4(8):1293–1308
15. Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC Jr, Sukumar S, Huso DL, Resar LM (2013) HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One 8(5):e63419. doi:10.1371/journal.pone.0063419
16. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S, Anttila S (2006) Increased expression of high mobility group A proteins in lung cancer. J Pathol 209(2):206–212. doi:10.1002/path.1960
17. Takahashi Y, Sawada G, Sato T, Kurashige J, Mima K, Matsumura T, Uchi R, Ueo H, Ishibashi M, Takano Y, Akiyoshi S, Eguchi H, Sudo T, Sugimachi K, Tanaka J, Kudo SE, Doki Y, Mori M, Mimori K (2013) Microarray analysis reveals that high mobility group A1 is involved in colorectal cancer metastasis. Oncol Rep 30(3):1488–1496. doi:10.3892/or.2013.2602
18. Chang ZG, Yang LY, Wang W, Peng JX, Huang GW, Tao YM, Ding X (2005) Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig Dis Sci 50(10):1764–1770. doi:10.1007/s10620-005-2934-9
19. van der Zee JA, ten Hagen TL, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, van Eijck CH (2010) Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer. Eur J Cancer 46(18):3393–3399. doi:10.1016/j.ejca.2010.07.024
20. Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, Belton A, Joseph B, Schuldenfrei A, Iacobuzio-Donahue CA, Maitra A, Resar LM (2010) HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 23(1):98–104. doi:10.1038/modpathol.2009.139
21. Liau SS, Whang E (2009) High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma. Surgeon 7(5):297–306
22. Qu Y, Wang Y, Ma J, Zhang Y, Meng N, Li H, Wang Y, Wei W (2013) Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis. PLoS One 8(7):e68724. doi:10.1371/journal.pone.0068724
23. Liu Z, Li X, He X, Jiang Q, Xie S, Yu X, Zhen Y, Xiao G, Yao K, Fang W (2011) Decreased expression of updated NESG1 in nasopharyngeal carcinoma: its potential role and preliminarily functional mechanism. Int J Cancer 128(11):2562–2571. doi:10.1002/ijc.25595
24. Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, Jiang Q, Song Y, Cheng C, Wang H, Zhao M, Fu Q, Lyu X, Chen Y, Fan Y, Liu Y, Li X, Fang W (2013) Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 4:e872. doi:10.1038/cddis.2013.376
25. Di Cello F, Shin J, Harbom K, Brayton C (2013) Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun 434(1):70–74. doi:10.1016/j.bbrc.2013.03.064
26. Wang EL, Qian ZR, Rahman MM, Yoshimoto K, Yamada S, Kudo E, Sano T (2010) Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology 56(4):501–509. doi:10.1111/j.1365-2559.2010.03495.x
27. Wang DS, Pan CC, Lai HC, Huang JM (2013) Expression of HMGA1 and ezrin in laryngeal squamous cell carcinoma. Acta Otolaryngol 133(6):626–632. doi:10.3109/00016489.2012.758388